References
- Kokjohn K, Bradley M, Griffiths B, Ghannoum M. Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole against dermatophytes and bacteria. Int J Dermatol 2003; 42: 11–17
- Korting, HC, Ollert, M, Abeck, D, for the GCDDSS Group. Results of german multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995; 39: 1206–1208.
- Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003; 65: 1–4
- Hay RJ. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 2001; 145: 3–8
- Seebacher C. The change of dermatophyte spectrum in dermatomycoses. Mycoses 2003; 46: 42–46
- Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003; 149: 5–9
- Evans EGV. Drug synergies and the potential for combination therapy in onychomycosis. Br J Dermatol 2003; 149: 11–13
- Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol 2001; 145: 21–26
- National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: Approved Standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA 2002
- Santos DA, Hamdan JS. Evaluation of broth microdilution antifungal susceptibility testing conditions for Trichophyton rubrum. J Clin Microbiol 2005; 43: 1917–1920
- Gupta AK, Kohli Y. In vitro susceptibility testing ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in-vitro evaluation of combination antifungal activity. Br J Dermatol 2003; 149: 296–305
- Barry AL, Pfaller MA, Brown SD, et al. Quality control limits of broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol 2005; 38: 3457–3459
- Nimura K, Niwano Y, Ishiduka S, Fukumoto R. Comparison of In vitro antifungal activities of topical antimycotics launched in 1990s in Japan. Int J Antimicrob Agents 2001; 18: 173–178
- Fernández-Torres B, Cabanes FJ, Carrillo-Muñoz A, et al. Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol 2002; 40: 3999–4003
- Develoux M. Griseofulvin. Ann Dermatol Venereol 2001; 128: 1317–1325
- Artis WM, Odle BM, Jones HE. Griseofulvin-resistant dermatophytosis correlates with In vitro resistance. Arch Dermatol 1981; 117: 16–19
- Lacaz, CS, Porto, E, Martins, JEC, Heins-Vaccari, EM, Melo, NT. 2002. Drogas antifúngicas. Terapêutica das micoses superficiais. Provas de sensibilidade In vitro. Dosagem sanguínea. In Tratado de Micologia Médica Lacaz. 9th ed. São Paulo: Sarvier, 2002: 998–1061.
- Olafsson JH, Sigurgeirsson B, Baran R. Combination therapy for onychomycosis. Br J Dermatol 2003; 149: 15–18
- Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol 2001; 141: 21–26
- Gomez-Lopez A, Cuenca-Estrella M, Mellado E, Rodriguez-Tudela JL. In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. Diagn Microbiol Infect Dis 2003; 45: 199–202